Despite pipelines from a few years ago suggesting that the inhaled insulin market was going to be busy the competition has now thinned, following Exubera’s demise and the subsequent lung cancer warnings.

All the events spanning back to 2003 that led to this situation are covered in the timeline, which spans the major players decision to pull out of the market and the knock-on effects for other businesses.

You can scroll from left to right by dragging with the left mouse button or use the bar at the bottom, zoom in and out with the plus and minus on the left and click on any bubble to find more information. Within each bubble the headline links to the complete article.